KR20210029161A - 합성 펩타이드, 프로드럭, 약학적 조성물 및 용도 - Google Patents

합성 펩타이드, 프로드럭, 약학적 조성물 및 용도 Download PDF

Info

Publication number
KR20210029161A
KR20210029161A KR1020207037684A KR20207037684A KR20210029161A KR 20210029161 A KR20210029161 A KR 20210029161A KR 1020207037684 A KR1020207037684 A KR 1020207037684A KR 20207037684 A KR20207037684 A KR 20207037684A KR 20210029161 A KR20210029161 A KR 20210029161A
Authority
KR
South Korea
Prior art keywords
seq
peptide
ala
trp
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020207037684A
Other languages
English (en)
Korean (ko)
Inventor
나시멘토 카이오 빅토르 마샤도 프란카 도
실바 디에고 알론소 로드리게스 도스 산토스 다
실바 펄라 빌라니 볼지스 다
마리아 엘레나 데 리마 페레즈 가르시아
실바 카롤리나 누니스 다
아드리아나 몬테이로 드 캐스트로 피멘타
마르셀라 누니스 드 멜로 브라가
파울로 구스타보 삼파이오 라카티바
파울라 주니오르 아이언 프란시스코 데
게르하드 막스 그로스
Original Assignee
바이오제우스 데센볼비멘토 데 프로듀토스 바이오파르마세우티코스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오제우스 데센볼비멘토 데 프로듀토스 바이오파르마세우티코스 filed Critical 바이오제우스 데센볼비멘토 데 프로듀토스 바이오파르마세우티코스
Publication of KR20210029161A publication Critical patent/KR20210029161A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020207037684A 2018-07-05 2019-07-04 합성 펩타이드, 프로드럭, 약학적 조성물 및 용도 Pending KR20210029161A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694162P 2018-07-05 2018-07-05
US62/694,162 2018-07-05
US16/502,215 US10905738B2 (en) 2018-07-05 2019-07-03 Synthetic peptides, prodrugs, pharmaceutical compositions and uses
US16/502,215 2019-07-03
PCT/BR2019/050249 WO2020006617A1 (en) 2018-07-05 2019-07-04 Synthetic peptides, prodrugs, pharmaceutical compositions and uses

Publications (1)

Publication Number Publication Date
KR20210029161A true KR20210029161A (ko) 2021-03-15

Family

ID=69059636

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207037684A Pending KR20210029161A (ko) 2018-07-05 2019-07-04 합성 펩타이드, 프로드럭, 약학적 조성물 및 용도

Country Status (8)

Country Link
US (1) US10905738B2 (https=)
EP (1) EP3818070B1 (https=)
JP (1) JP7317956B2 (https=)
KR (1) KR20210029161A (https=)
CN (1) CN112654634B (https=)
BR (1) BR112021000105A2 (https=)
CA (1) CA3104183A1 (https=)
WO (1) WO2020006617A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026507422A (ja) * 2023-02-17 2026-03-04 バイオゼウス バイオファーマシューティカル エス．エー． 性機能障害の治療のための局所用ペプチド製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
AT387234B (de) 1987-03-05 1988-12-27 Vogelbusch Gmbh Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen
US5470949A (en) 1992-12-15 1995-11-28 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for making amino acid glycosides and glycopeptides
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
US7585523B2 (en) 2002-08-27 2009-09-08 Targeted Medical Pharma Composition and method to augment and sustain neurotransmitter production
CA2560956A1 (en) 2004-03-29 2005-10-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
CN101563102B (zh) 2006-09-22 2014-12-17 德克萨斯系统大学董事会 治疗内皮功能障碍的方法
KR20090115852A (ko) 2007-01-19 2009-11-09 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
BRPI0800596A2 (pt) 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
CN101585872A (zh) 2008-05-23 2009-11-25 成都蓉药集团四川长威制药有限公司 重组蛛毒蛋白、其制备方法和表达载体以及用于治疗ed的药物
KR20130139254A (ko) 2010-11-09 2013-12-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 피부 침투 및 세포 진입（ｓｐａｃｅ） 펩타이드 및 그의 사용방법
PT2899198T (pt) * 2012-08-20 2018-06-29 Univ Federal De Minas Gerais Ufmg Péptido sintético pntx(19), composições farmacêuticas e utilização
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2015162195A1 (en) 2014-04-23 2015-10-29 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
WO2017068388A2 (pt) 2015-09-18 2017-04-27 Universidade Federal De Minas Gerais - Ufmg Uso do peptideo sintetico pntx-19 para tratamento de dor
KR101613302B1 (ko) 2015-12-30 2016-04-18 (주)넥스젠바이오텍 Sv82 폴리펩타이드 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물
KR101636851B1 (ko) 2016-06-03 2016-07-06 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 열 안정성 인간 상피세포성장인자-거미독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선 및 탄력 유지용 화장료 조성물

Also Published As

Publication number Publication date
WO2020006617A1 (en) 2020-01-09
US20200108118A1 (en) 2020-04-09
US10905738B2 (en) 2021-02-02
CA3104183A1 (en) 2020-01-09
CN112654634A (zh) 2021-04-13
JP2021530562A (ja) 2021-11-11
CN112654634B (zh) 2022-05-27
JP7317956B2 (ja) 2023-07-31
BR112021000105A2 (pt) 2021-03-30
EP3818070A4 (en) 2022-03-16
EP3818070B1 (en) 2026-03-11
EP3818070A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
US12285460B2 (en) Pharmaceutical compositions
JP2793719B2 (ja) サイトカイン抑制剤
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
ES2594706T3 (es) Péptidos biológicamente activos
ES2632787T3 (es) Análogos agonistas del receptor opioide mu de las endomorfinas
ES2724932T3 (es) Péptidos neuroprotectores
ES2750258T3 (es) Métodos y composiciones para la prevención o tratamiento del síndrome de Barth
JP4147329B2 (ja) 液体形態の改良された安定性を有するコルチコトロピン放出因子の医薬製剤
ES3019509T3 (en) Pharmaceutical composition of glp-1/glp-2 dual agonists
US20100004165A1 (en) Novel Protein Transduction Domains and Uses Therefor
WO2022194238A1 (en) New peptide conjugates
JP7317956B2 (ja) 合成ペプチド、プロドラッグ、医薬組成物および使用
DE60133654D1 (de) Arzneimittel enthaltend analgetische peptide
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof
HK40043121B (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
HK40043121A (en) Synthetic peptides, prodrugs, pharmaceutical compositions and uses
CN105636975A (zh) 抗炎三肽
CA3238619A1 (en) Pharmaceutical compositions for the treatment of visceral pain
US7829528B2 (en) Compositions and methods for treating STAT-6 associated diseases or conditions
HK1180344A (en) Mu opioid receptor agonist analogs of the endomorphins
HK1180344B (en) Mu opioid receptor agonist analogs of the endomorphins

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000